Wall Street analysts forecast that Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) will post earnings of ($0.68) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Tonix Pharmaceuticals Holding Corp.’s earnings, with the highest EPS estimate coming in at ($0.64) and the lowest estimate coming in at ($0.71). Tonix Pharmaceuticals Holding Corp. reported earnings per share of ($2.60) during the same quarter last year, which would indicate a positive year-over-year growth rate of 73.8%. The firm is scheduled to announce its next quarterly earnings results on Thursday, November 9th.

On average, analysts expect that Tonix Pharmaceuticals Holding Corp. will report full-year earnings of ($2.96) per share for the current financial year, with EPS estimates ranging from ($3.10) to ($2.81). For the next financial year, analysts expect that the firm will report earnings of ($2.31) per share, with EPS estimates ranging from ($2.79) to ($1.60). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that cover Tonix Pharmaceuticals Holding Corp..

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last released its earnings results on Monday, August 14th. The company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.13.

A number of research firms have recently weighed in on TNXP. Aegis began coverage on shares of Tonix Pharmaceuticals Holding Corp. in a research note on Monday, June 26th. They issued a “buy” rating and a $10.00 price target on the stock. Dawson James reaffirmed a “buy” rating and issued a $9.00 price target on shares of Tonix Pharmaceuticals Holding Corp. in a research note on Wednesday, August 23rd. Drexel Hamilton began coverage on shares of Tonix Pharmaceuticals Holding Corp. in a research note on Tuesday, August 22nd. They issued a “buy” rating on the stock. Finally, Roth Capital raised shares of Tonix Pharmaceuticals Holding Corp. from a “neutral” rating to a “buy” rating and set a $6.00 price target on the stock in a research note on Friday, August 18th. They noted that the move was a valuation call. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $8.33.

COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Expect Tonix Pharmaceuticals Holding Corp. (TNXP) Will Announce Earnings of -$0.68 Per Share” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/08/30/zacks-analysts-expect-tonix-pharmaceuticals-holding-corp-tnxp-will-announce-earnings-of-0-68-per-share.html.

Tonix Pharmaceuticals Holding Corp. (TNXP) traded down 0.79% during midday trading on Friday, reaching $3.76. The company’s stock had a trading volume of 133,538 shares. The firm has a 50-day moving average price of $3.75 and a 200 day moving average price of $3.39. The stock’s market capitalization is $28.23 million. Tonix Pharmaceuticals Holding Corp. has a 52-week low of $2.85 and a 52-week high of $27.50.

In related news, Director Ernest Mario sold 6,105 shares of the company’s stock in a transaction on Friday, June 30th. The shares were sold at an average price of $4.28, for a total value of $26,129.40. Following the completion of the sale, the director now directly owns 63,073 shares in the company, valued at $269,952.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Seth Lederman acquired 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The stock was acquired at an average price of $3.00 per share, with a total value of $60,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 11,166 shares of the company’s stock, valued at approximately $33,498. The disclosure for this purchase can be found here. Insiders bought 50,000 shares of company stock worth $188,050 over the last ninety days. 4.00% of the stock is currently owned by company insiders.

A number of large investors have recently modified their holdings of the company. Citadel Advisors LLC acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. during the first quarter worth about $119,000. Dialectic Capital Management LP acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. during the first quarter worth about $187,000. Vanguard Group Inc. boosted its stake in shares of Tonix Pharmaceuticals Holding Corp. by 28.8% in the second quarter. Vanguard Group Inc. now owns 184,377 shares of the company’s stock worth $799,000 after buying an additional 41,264 shares in the last quarter. B. Riley Financial Inc. acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. during the second quarter worth about $1,637,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Tonix Pharmaceuticals Holding Corp. by 108.4% in the fourth quarter. Renaissance Technologies LLC now owns 774,603 shares of the company’s stock worth $364,000 after buying an additional 402,898 shares in the last quarter. Hedge funds and other institutional investors own 23.76% of the company’s stock.

Tonix Pharmaceuticals Holding Corp. Company Profile

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

Get a free copy of the Zacks research report on Tonix Pharmaceuticals Holding Corp. (TNXP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Receive News & Stock Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related stocks with our FREE daily email newsletter.